Target validation in drug discovery:
Saved in:
| Format: | Electronic eBook |
|---|---|
| Language: | English |
| Published: |
Amsterdam ; Boston
Academic Press
2007
|
| Subjects: | |
| Item Description: | Print version record |
| Physical Description: | 1 online resource (xii, 279 pages) illustrations |
| ISBN: | 9780123693938 0123693934 9780080465975 0080465978 |
Staff View
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV045341814 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 181206s2007 |||| o||u| ||||||eng d | ||
| 020 | |a 9780123693938 |9 978-0-12-369393-8 | ||
| 020 | |a 0123693934 |9 0-12-369393-4 | ||
| 020 | |a 9780080465975 |9 978-0-08-046597-5 | ||
| 020 | |a 0080465978 |9 0-08-046597-8 | ||
| 035 | |a (ZDB-4-ENC)ocn162130366 | ||
| 035 | |a (OCoLC)162130366 | ||
| 035 | |a (DE-599)BVBBV045341814 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 082 | 0 | |a 615/.19 |2 22 | |
| 245 | 1 | 0 | |a Target validation in drug discovery |c editors, Brian W. Metcalf and Susan Dillon |
| 264 | 1 | |a Amsterdam ; Boston |b Academic Press |c 2007 | |
| 300 | |a 1 online resource (xii, 279 pages) |b illustrations | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 500 | |a Print version record | ||
| 505 | 8 | |a This work presents a comprehensive contemporary framework for approaching target validation in drug discovery. It begins with a detailed description of new enabling technologies, including aptamers, RNA interference, functional genomics, and proteomics. The next section looks at biologic drug development with in-depth discussion of lessons learned from such well-known cases as Erbitux, Herceptin, and Avastin. Additional targets known as "second generation" drugs, which can be identified when disease pathways are validated by biologics, present new possible small molecule therapeutics and serve as the focus of the final section of the book | |
| 650 | 4 | |a Drug Design | |
| 650 | 4 | |a Drug Delivery Systems | |
| 650 | 4 | |a Technology, Pharmaceutical | |
| 650 | 4 | |a Biopharmaceutics | |
| 650 | 4 | |a Medicaments / Developpement | |
| 650 | 4 | |a Medicaments / Essais cliniques | |
| 650 | 4 | |a Criblage a haut debit (Developpement des medicaments) | |
| 650 | 7 | |a MEDICAL / Drug Guides |2 bisacsh | |
| 650 | 7 | |a MEDICAL / Pharmacology |2 bisacsh | |
| 650 | 7 | |a MEDICAL / Pharmacy |2 bisacsh | |
| 650 | 7 | |a MEDICAL / Nursing / Pharmacology |2 bisacsh | |
| 650 | 7 | |a Drug development |2 fast | |
| 650 | 7 | |a Drugs / Testing |2 fast | |
| 650 | 7 | |a High throughput screening (Drug development) |2 fast | |
| 650 | 7 | |a Medicaments / Mise au point |2 ram | |
| 650 | 7 | |a Medicaments / Essais cliniques |2 ram | |
| 650 | 7 | |a Criblage pharmacologique |2 ram | |
| 650 | 4 | |a Drug development |a Drugs |x Testing |a High throughput screening (Drug development) | |
| 700 | 1 | |a Metcalf, Brian W. |e Sonstige |4 oth | |
| 700 | 1 | |a Dillon, Susan |d 1952- |e Sonstige |4 oth | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |t Target validation in drug discovery |d Amsterdam ; Boston : Academic Press, 2007 |z 0123693934 |z 9780123693938 |
| 912 | |a ZDB-4-ENC | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-030728517 | ||
Record in the Search Index
| _version_ | 1804179158901719040 |
|---|---|
| any_adam_object | |
| building | Verbundindex |
| bvnumber | BV045341814 |
| collection | ZDB-4-ENC |
| contents | This work presents a comprehensive contemporary framework for approaching target validation in drug discovery. It begins with a detailed description of new enabling technologies, including aptamers, RNA interference, functional genomics, and proteomics. The next section looks at biologic drug development with in-depth discussion of lessons learned from such well-known cases as Erbitux, Herceptin, and Avastin. Additional targets known as "second generation" drugs, which can be identified when disease pathways are validated by biologics, present new possible small molecule therapeutics and serve as the focus of the final section of the book |
| ctrlnum | (ZDB-4-ENC)ocn162130366 (OCoLC)162130366 (DE-599)BVBBV045341814 |
| dewey-full | 615/.19 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615/.19 |
| dewey-search | 615/.19 |
| dewey-sort | 3615 219 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02786nmm a2200577zc 4500</leader><controlfield tag="001">BV045341814</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">181206s2007 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780123693938</subfield><subfield code="9">978-0-12-369393-8</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0123693934</subfield><subfield code="9">0-12-369393-4</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780080465975</subfield><subfield code="9">978-0-08-046597-5</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0080465978</subfield><subfield code="9">0-08-046597-8</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-4-ENC)ocn162130366</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)162130366</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV045341814</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615/.19</subfield><subfield code="2">22</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Target validation in drug discovery</subfield><subfield code="c">editors, Brian W. Metcalf and Susan Dillon</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Amsterdam ; Boston</subfield><subfield code="b">Academic Press</subfield><subfield code="c">2007</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (xii, 279 pages)</subfield><subfield code="b">illustrations</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Print version record</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">This work presents a comprehensive contemporary framework for approaching target validation in drug discovery. It begins with a detailed description of new enabling technologies, including aptamers, RNA interference, functional genomics, and proteomics. The next section looks at biologic drug development with in-depth discussion of lessons learned from such well-known cases as Erbitux, Herceptin, and Avastin. Additional targets known as "second generation" drugs, which can be identified when disease pathways are validated by biologics, present new possible small molecule therapeutics and serve as the focus of the final section of the book</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Design</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Delivery Systems</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Technology, Pharmaceutical</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Biopharmaceutics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medicaments / Developpement</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medicaments / Essais cliniques</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Criblage a haut debit (Developpement des medicaments)</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Drug Guides</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Pharmacology</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Pharmacy</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Nursing / Pharmacology</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Drug development</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Drugs / Testing</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">High throughput screening (Drug development)</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Medicaments / Mise au point</subfield><subfield code="2">ram</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Medicaments / Essais cliniques</subfield><subfield code="2">ram</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Criblage pharmacologique</subfield><subfield code="2">ram</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug development</subfield><subfield code="a">Drugs</subfield><subfield code="x">Testing</subfield><subfield code="a">High throughput screening (Drug development)</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Metcalf, Brian W.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Dillon, Susan</subfield><subfield code="d">1952-</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="t">Target validation in drug discovery</subfield><subfield code="d">Amsterdam ; Boston : Academic Press, 2007</subfield><subfield code="z">0123693934</subfield><subfield code="z">9780123693938</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-ENC</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-030728517</subfield></datafield></record></collection> |
| id | DE-604.BV045341814 |
| illustrated | Illustrated |
| indexdate | 2024-07-10T08:15:25Z |
| institution | BVB |
| isbn | 9780123693938 0123693934 9780080465975 0080465978 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-030728517 |
| oclc_num | 162130366 |
| open_access_boolean | |
| physical | 1 online resource (xii, 279 pages) illustrations |
| psigel | ZDB-4-ENC |
| publishDate | 2007 |
| publishDateSearch | 2007 |
| publishDateSort | 2007 |
| publisher | Academic Press |
| record_format | marc |
| spelling | Target validation in drug discovery editors, Brian W. Metcalf and Susan Dillon Amsterdam ; Boston Academic Press 2007 1 online resource (xii, 279 pages) illustrations txt rdacontent c rdamedia cr rdacarrier Print version record This work presents a comprehensive contemporary framework for approaching target validation in drug discovery. It begins with a detailed description of new enabling technologies, including aptamers, RNA interference, functional genomics, and proteomics. The next section looks at biologic drug development with in-depth discussion of lessons learned from such well-known cases as Erbitux, Herceptin, and Avastin. Additional targets known as "second generation" drugs, which can be identified when disease pathways are validated by biologics, present new possible small molecule therapeutics and serve as the focus of the final section of the book Drug Design Drug Delivery Systems Technology, Pharmaceutical Biopharmaceutics Medicaments / Developpement Medicaments / Essais cliniques Criblage a haut debit (Developpement des medicaments) MEDICAL / Drug Guides bisacsh MEDICAL / Pharmacology bisacsh MEDICAL / Pharmacy bisacsh MEDICAL / Nursing / Pharmacology bisacsh Drug development fast Drugs / Testing fast High throughput screening (Drug development) fast Medicaments / Mise au point ram Medicaments / Essais cliniques ram Criblage pharmacologique ram Drug development Drugs Testing High throughput screening (Drug development) Metcalf, Brian W. Sonstige oth Dillon, Susan 1952- Sonstige oth Erscheint auch als Druck-Ausgabe Target validation in drug discovery Amsterdam ; Boston : Academic Press, 2007 0123693934 9780123693938 |
| spellingShingle | Target validation in drug discovery This work presents a comprehensive contemporary framework for approaching target validation in drug discovery. It begins with a detailed description of new enabling technologies, including aptamers, RNA interference, functional genomics, and proteomics. The next section looks at biologic drug development with in-depth discussion of lessons learned from such well-known cases as Erbitux, Herceptin, and Avastin. Additional targets known as "second generation" drugs, which can be identified when disease pathways are validated by biologics, present new possible small molecule therapeutics and serve as the focus of the final section of the book Drug Design Drug Delivery Systems Technology, Pharmaceutical Biopharmaceutics Medicaments / Developpement Medicaments / Essais cliniques Criblage a haut debit (Developpement des medicaments) MEDICAL / Drug Guides bisacsh MEDICAL / Pharmacology bisacsh MEDICAL / Pharmacy bisacsh MEDICAL / Nursing / Pharmacology bisacsh Drug development fast Drugs / Testing fast High throughput screening (Drug development) fast Medicaments / Mise au point ram Medicaments / Essais cliniques ram Criblage pharmacologique ram Drug development Drugs Testing High throughput screening (Drug development) |
| title | Target validation in drug discovery |
| title_auth | Target validation in drug discovery |
| title_exact_search | Target validation in drug discovery |
| title_full | Target validation in drug discovery editors, Brian W. Metcalf and Susan Dillon |
| title_fullStr | Target validation in drug discovery editors, Brian W. Metcalf and Susan Dillon |
| title_full_unstemmed | Target validation in drug discovery editors, Brian W. Metcalf and Susan Dillon |
| title_short | Target validation in drug discovery |
| title_sort | target validation in drug discovery |
| topic | Drug Design Drug Delivery Systems Technology, Pharmaceutical Biopharmaceutics Medicaments / Developpement Medicaments / Essais cliniques Criblage a haut debit (Developpement des medicaments) MEDICAL / Drug Guides bisacsh MEDICAL / Pharmacology bisacsh MEDICAL / Pharmacy bisacsh MEDICAL / Nursing / Pharmacology bisacsh Drug development fast Drugs / Testing fast High throughput screening (Drug development) fast Medicaments / Mise au point ram Medicaments / Essais cliniques ram Criblage pharmacologique ram Drug development Drugs Testing High throughput screening (Drug development) |
| topic_facet | Drug Design Drug Delivery Systems Technology, Pharmaceutical Biopharmaceutics Medicaments / Developpement Medicaments / Essais cliniques Criblage a haut debit (Developpement des medicaments) MEDICAL / Drug Guides MEDICAL / Pharmacology MEDICAL / Pharmacy MEDICAL / Nursing / Pharmacology Drug development Drugs / Testing High throughput screening (Drug development) Medicaments / Mise au point Criblage pharmacologique Drug development Drugs Testing High throughput screening (Drug development) |
| work_keys_str_mv | AT metcalfbrianw targetvalidationindrugdiscovery AT dillonsusan targetvalidationindrugdiscovery |